Peter Young is a Venture Partner at Pappas Capital, and brings to his investment approach thirty-five years of experience in the biopharma sector. The former Vice President and Therapy Head at Glaxo Wellcome in the mid-1990s, Peter led the global introduction of combination HIV therapies that revolutionized HIV treatment, quintupled Glaxo’s HIV sales, and maintained leadership on global treatment access. Peter has since served as CEO of two private start-ups, a vaccine company that raised over $80 million in NIH, HIV, and biodefense grants, and a specialty pharmaceutical company he led to a successful exit. In a podcast recorded at the BIO International conference, Peter discusses the ramifications of the Trump Administration’s proposals for international reference pricing in Medicare Part B, as well as how to balance the higher prices being driven by smaller, targeted indications and the need to support the natural movement of science in rare therapies. We also discuss the ‘hot-button’ issues around the orphan drug legislation and how we can constructively move forward without throwing the orphan baby out with the bathwater. This podcast is made possible with the support of EUCOPE.See omnystudio.com/listener for privacy information.